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Targeted gene transfer into human cells has previously been achieved with spleen necrosis virus (SNV)-derived vector
particles harboring envelope (Env) proteins which carry single chain Fv (scFv) domains derived from antibodies. Such cell
targeting vectors have been found to directly transduce human cells expressing the cell surface molecules recognized by the
respective scFv. In an attempt to achieve targeted gene transfer into epidermal growth factor receptor (EGFR)-positive human
cells, SNV vector particles carrying a surface (SU) envelope protein N-terminally modified with the EGF domain and the
wildtype transmembrane protein were generated. However, direct transduction of EGFR-positive cells was not detected.
Canine D17 cells, which can be infected by wildtype SNV, were also not transduced. Infectivity of D17 cells was restored by
removal of the EGF modification via cleavage of a factor Xa site located between the EGF domain and the SU protein or by
blocking the EGFRs on the cell surface by EGF treatment. The properties of SNV-EGF vector particles as described here are
similar to those of murine leukemia virus-derived vector particles harboring envelope proteins modified with a growth
factor-derived domain. It seems therefore that, although scFv-modified SNV allows direct cell targeting, EGF-modified SNVKey Words: spleen necrosis virus; murine leukaemia viru
INTRODUCTION
Modifying the tropism of viruses by genetic engineer-
ing of their envelope (Env) proteins is a major goal
toward the development of efficient gene transfer vec-
tors. Such vectors would allow gene transfer (transduc-
tion) into selected cell types, a strategy often termed cell
targeting. Cell targeting vectors may also help our un-
derstanding of the molecular mechanism underlying vi-
rus cell entry.
One of the initial strategies to develop retroviral cell
targeting vectors involved the modification of the viral
surface envelope (SU) glycoprotein by N-terminal inser-
tion of either a single chain antibody fragment (scFv) or
a growth factor-derived peptide ligand. These new SU
domains were shown to mediate contact of the viral SU
protein with the respective human cell surface proteins
recognized by the scFv or the ligand (Ager et al., 1996;
Chu et al., 1994; reviewed in Buchholz et al., 1999).
Moloney murine leukemia virus (MoMLV), the prototype
ecotropic C-type retrovirus, and spleen necrosis virus
(SNV), an avian C-type retrovirus, have initially been used
for these cell targeting approaches (see below) because
both the viruses and the respective vector particles are
unable to infect human cells due to a block at the level of
cell entry (Albritton et al., 1989; Gautier et al., 2000).
1 To whom correspondence and reprint requests should be ad-
dressed at Dept. of Medical Biotechnology, Paul-Ehrlich-Institut, Paul-0042-6822/02 $35.00
© 2002 Elsevier Science (USA)
All rights reserved.
106eting; EGF; viral entry; gene transfer.
Although the SNV Env proteins are more closely re-
lated to those of the type D retroviruses, both the SNV
and the MLV Env proteins share a similar overall struc-
ture. They are homotrimers composed of heterodimers
consisting of the SU and the transmembrane (TM) pro-
teins. The SU protein mediates contact to the viral re-
ceptor on permissive cells during cell entry, whereas the
TM envelope protein anchors the Env protein complex in
the viral membrane and promotes fusion of the viral and
the cellular membranes, a prerequisite of retroviral cell
entry. Fusion is mediated by the so-called fusion peptide
at the N-terminus of the TM. As in all retroviruses, the SU
and TM proteins arise from intracellular proteolytic
cleavage of the Env precursor protein.
For SNV, targeted gene transfer into human cells has
been achieved by use of a number of scFv molecules,
including scFvs directed against human cancer antigens,
CD34, or the transferrin receptor. In many of these cases,
considerable gene transfer efficiencies and high vector
titers of up to 2  105 EFU/ml were achieved (Chu and
Dornburg, 1997; Jiang et al., 1998). Recently, we demon-
strated that scFv molecules mediating selective targeting
of SNV vectors into human T-cells can be generated by
preselection of cell surface binding scFvs from phage
display libraries (Engelstaedter et al., 2000). In most of
these cases, the scFv was covalently linked to the TM
protein and coexpressed with the wildtype SNV Env
proteins in packaging cell lines. As a result, a very smallallows only indirect cell targeting. © 2002 Elsevier Science (USA
Ehrlich-Strasse 51-59, 63225 Langen, Germany. Fax: (49) 6103/
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vector particles. Generation of high titer vectors always
involved selection of suitable packaging cell clones,
whereas very low or no titers were achieved by using
transiently generated packaging cells (Chu et al., 1994).
In contrast to SNV-derived cell targeting vectors,
MoMLV-derived vectors containing SU proteins N-termi-
nally modified by one of a series of different scFvs and
growth factor domains usually showed inefficient cell
entry and gene transfer. In most cases, the vector titers
reported in human cells were below 103 EFU/ml (Ager et
al., 1996; Schnierle et al., 1996; Lee et al., 1999), although
binding of these vector particles to human cells was
observed. Even when a MoMLV-derived scFv-TM was
coexpressed with wildtype MoMLV Env in packaging cell
lines, no cell entry of the respective MoMLV vector par-
ticles was detected (Lee et al., 1999). This seemed to
indicate a striking difference between MoMLV- and SNV-
derived vectors harboring modified SU proteins. How-
ever, the transduction properties of SNV vector particles
containing SU proteins N-terminally fused to growth fac-
tor domains and the wildtype TM protein have not yet
been analyzed.
The observation that SU-modified MoMLV vector par-
ticles were able to bind to human cells in the absence of
transduction led to the development of an indirect cell
targeting approach based on amphotropic MLV 4070A.
Amphotropic MLV-derived vector particles are able to
transduce almost all proliferating human cells. When
high-affinity growth factors like epidermal growth factor
(EGF) (Cosset et al., 1995), stem cell factor (SCF) (Field-
ing et al., 1998), or insulin-like growth factor (IGF-I)
(Chadwick et al., 1999) were N-terminally fused to the
amphotropic MLV SU protein, inhibition of virus entry into
human cells expressing the respective growth factor
receptors was observed. This effect was shown to be
due to sequestration of the virus by the targeted receptor.
This mechanism prevented contact of the virus with its
natural receptor Ram-1 (Miller et al., 1994). Based on this
observation protease activatable MLV vectors have been
generated by inserting protease cleavable linker pep-
tides between SU and the N-terminally fused growth
factor domain. Exposure of such vector particles to the
relevant protease in vitro results in cleavage and removal
of the growth factor domain. This, in turn, removes the
block to human cell entry and leads to restoration of
virus entry and gene transfer. Initially a factor Xa cleav-
age site was used; later vectors activatable by mem-
brane-type matrix metalloproteinase (MT-MMP) or plas-
min were generated (Nilson et al., 1996; Peng et al., 1997,
1999). We describe here the surprising observation that
SNV vectors harboring an SU protein modified with the
EGF domain (named SNV-EGF vectors) show character-
istics similar to EGF-modified amphotropic MLV vectors.
The SNV-EGF vectors bind to EGF receptor (EGFR) ex-
pressing cells in the absence of cell entry and transduc-
tion. Cell entry into EGFR-positive D17 cells, which can
be infected by wildtype SNV, is also inhibited by the SU
modification. Removal of the EGF modification by in vitro
protease cleavage restores infectivity.
RESULTS
Envelope gene constructs modified by EGF domains
Envelope gene constructs able to express EGF-modi-
fied SNV Env proteins were constructed. The EGF do-
main was inserted between the leader peptide sequence
and the first amino acid of the N-terminus of the SNV SU
or TM proteins, respectively. A factor Xa cleavable linker
was introduced at the C-terminus of the EGF domain to
allow analysis of the effects of the EGF targeting domain
on vector tropism. The primary structure of the Env pro-
teins encoded by the resulting plasmids pRD134-EGF
and pTC53-EGF is depicted in Fig. 1. The natural pro-
tease cleavage site located between the SU and the TM
proteins was retained in construct RD134-EGF, but not in
construct TC53-EGF. The latter gene construct was de-
rived from plasmid pTC53-scFV, which has been used for
the generation of scFv-TM and wildtype SNV Env-incor-
FIG. 1. Schematic diagram of the envelope gene constructs. (A) In
construct RD134-EGF the EGF domain is fused to the N-terminus of the
SNV SU protein protein (EGF-SU-TM). (B) In construct TC53-EGF the
EGF domain is fused to the N-terminus of the SNV TM protein (EGF-
TM). (C) In construct EXA the EGF domain is fused to the N-terminus of
the MLV SU protein. The factor Xa cleavage site is underlined. Eukary-
otic control elements allow efficient expression in mammalian cells. LP,
leader peptide.
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porating vector particles able to transduce human cells
(Chu and Dornburg, 1994). For comparison of SNV and
MLVampho vectors, an EGF-modified MLVampho-EGF
gene analogous to RD134-EGF was constructed (EXA,
Fig. 1C).
Cell surface expression and incorporation into SNV
particles of SNV-derived EGF-TM and EGF-SU/TM
proteins
The cell surface expression of the modified Env pro-
teins encoded by pRD134-EGF and pTC53-EGF was an-
alyzed following transfection into 293T cells. FACS anal-
ysis using an anti-EGF antibody (see Materials and
Methods for details) revealed efficient cell surface ex-
pression of the EGF-SU protein (Fig. 2A). In contrast, the
cell surface expression of the EGF-TM protein encoded
by pTC53-EGF was only marginally detected. Cell sur-
face expression did not increase if the EGF-TM was
cotransfected with plasmid pRD134 encoding the wild-
type SNV Env proteins (data not shown). However, stain-
ing of pTC53-EGF-transfected permeabilized 293T cells
with the anti-EGF antibody demonstrated intracellular
expression of the EGF-TM protein (not shown).
To analyze the possible incorporation of the EGF-
modified Env proteins into SNV vector particles, triple
transfection of 293T cells was performed with plasmid
pRD136 encoding SNV gag/pol, an SNV psi site-positive
lacZ reporter gene (CXL), and the respective envelope
gene constructs. Supernatants of the transfected cells
were collected and applied to Western blot analysis. The
number of particles collected for Western blot analysis
was estimated by determining reverse transcriptase ac-
tivity in the supernatants. As the monoclonal anti-EGF
antibody used for FACS analysis did not react against
denatured protein (data not shown), we used antibody
11A25 directed against the SNV TM protein. It was as-
sumed that the incorporation of TM into SNV correlated
with SU or EGF-SU incorporation. Similar amounts of TM
protein were detected in particles released from
pRD134-EGF- and pRD134-transfected packaging cells,
indicating that the EGF-SU protein was as well incorpo-
rated into SNV particles as the wildtype Env proteins (Fig.
FIG. 2. Expression and incorporation of EGF-modified SNV Env proteins into SNV-derived vector particles. (A) FACS assays were performed 48 h
posttransfection of 293T cells with the expression plasmids indicated. Cells were stained with an anti-EGF antibody (black histograms) versus no
primary antibody (white histograms). (B) Incorporation of the Env proteins into SNV particles. Supernatants from 3 107 untransfected 293T cells (lane
1, untransfected) or transiently transfected cells producing WT (lane 2, pRD134) or EGF-displaying particles (lane 3, pRD134-EGF) were pelleted by
ultracentrifugation and used for Western blot analysis using anti-SNV-TM antibody. The position of the band corresponding to the SNV TM protein is
indicated by an arrow.
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2B, lanes 2 (WT-Env) and 3 (EGF-SU/TM)). As expected
from the results of the FACS analysis, the EGF-TM pro-
tein, encoded by pTC53-EGF, was not detectable in SNV
particles if expressed alone or in conjunction with the
wildtype Env proteins (data not shown). From these ex-
periments we concluded that the EGF-SU protein is effi-
ciently expressed and incorporated into SNV particles,
whereas the EGF-TM protein is retained mostly within
the cell and therefore not incorporated into SNV vector
particles in amounts detectable by Western blot analysis.
Absence of gene transfer into EGFR-positive cells by
SNV vector particles harboring EGF-modified Env
proteins
The vector particles were then tested for their ability to
transfer the lacZ gene encoded by the respective expres-
sion vector CXI into the human tumor cell lines HT1080
and A431. More than 95% of these cell lines expressed
high levels of EGFR at their surface as tested by FACS
(data not shown). The cells were also incubated with
vector particles generated with the EGF-SU or the
EGF-TM proteins alone or in combination with the wild-
type Env proteins (WT SU-TM), respectively. None of
these vector particles allowed transduction of HT1080 or
A431 cells. However, transduction of these cells was
observed when SNV particles pseudotyped with the
VSV-G protein were used, excluding the possibility that
the SNV reporter gene CXL was not expressed in HT1080
or A431 cells (Table 1). In addition, the supernatants
were titrated on SNV permissive D17 cells to measure
the numbers of infectious vector particles produced by
the respective packaging cells. The reason for the low
titer of SNV vector particles containing the EGF-SU and
the wildtype TM protein on D17 cells was elucidated in
experiments described below.
Although the transient transfection of 293T cells with
RD134 encoding the wildtype SNV Env proteins allowed
the generation of SNV vectors with titers of above
105 EFU/ml, it seemed possible that successful targeting
using SNV vector particles depends on the generation of
stable packaging cell lines. Stable packaging cell lines
had previously been successfully generated using ca-
nine DSH-cxl cells expressing SNV gag/pol, CXL, and
wildtype SNV env (Jiang et al., 1998). We therefore co-
transfected DSH-cxl cells with plasmid pTC53-EGF and
selected stable cell clones by use of their resistance to
zeocin. After selection 25 different cell clones were col-
lected and separately tested for their ability to release
infectious vector particles. Titers up to 1  106 EFU/ml
were determined by titration on D17 cells, which are
permissive for wildtype SNV (not shown). However, when
the same supernatants were tested on HT1080 and A431
cells, no gene transfer was detected (not shown). Thus,
transduction of human EGFR-positive cells using SNV
vector particles harboring EGF-TM proteins and wildtype
SNV Env proteins was not observed using transiently
generated or stable packaging cells.
Inhibition of D17 cell transduction by SNV vectors
harboring EGF-SU/TM envelope proteins and
restoration of D17 cell transduction by removal of the
EGF domain or blockage of EGFRs
The transduction of D17 cells with SNV vector particles
harboring EGF-SU/TM proteins (named SNV-EGF vec-
tors) was analyzed in more detail. As D17 cells can be
infected by SNV and by amphotropic MLV, we generated
as a control MLV particles harboring the MLV EGF-SU
and the MLV TM proteins. As in the SNV env constructs,
the EGF domain linked to the SU protein by a factor Xa
cleavage site was inserted between the leader peptide
and the N-terminus of the processed MLV SU protein
(Fig. 1C). The corresponding vector was named MLV-
EGF and analyzed in parallel with the SNV-EGF vector.
MLV vector stocks were generated by triple transfection
of 293T cells with the plasmids pEXA, pHIT60 (MLV
gag-pol; see Materials and Methods), and pMFGnlslacZ
(MLV psi-positive lacZ expression vector). The transduc-
tion properties of the MLV-EGF and SNV-EGF vector
particles were analyzed in D17 cells as such or following
pretreatment with factor Xa as previously described for
MLV (Fig. 3; Nilson et al., 1996). Untreated vector parti-
cles gave a background titer of 102 EFU/ml (EGF-MLV) or
lower (EGF-SNV). Upon factor Xa treatment the titers of
both vector types increased dramatically. While the EGF-
MLV vector titer increased about 100-fold, infectivity of
the EGF-SNV vector was 104 times higher following pre-
treatment with factor Xa protease. Preincubating D17
cells with soluble EGF before the vector particles were
added had a similar effect, although the activation of the
EGF-MLV vector was slightly more efficient than that of
the EGF-SNV vector. Maximal levels of activation were
obtained for both viruses when factor Xa treatment and
EGF treatment were combined. Then, titers similar to that
obtained with vector particles carrying the correspond-
TABLE 1
Titers of SNV Vector Particles Harboring EGF-Modified Env
Proteins in Canine D17 and Two Human Cell Lines
Envelope
Titer (EFU/ml)a
D17 A431 HT1080
WT SU-TM 1.2 105 10 10
EGF-SU/TM 10 10 10
WT SU-TM EGF-SU/TM 9 103 10 10
WT-SU-TM EGF-TM 6.4 104 10 10
VSV-G 3.6 103 3.3 104 8 102
a Mean values of two experiments are given. Standard deviations
were below 50%.
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ing unmodified Env proteins were observed. Expression
of EGFR at the surface of D17 cells was verified by FACS
analysis using fluorescently labeled EGF. The expression
level of EGF in D17 cells was comparable to that of NIH
3T3 cells and slightly below that of HT1080 cells, which
served as a positive control (not shown). Also on MDCK
cells, another canine cell line permissive for SNV ex-
pressing high levels of EGFR (Hobert et al., 1999), the
titer of the EGF-SNV vector was strongly reduced. Simi-
larly, as shown for D17 cells, titer could be fully restored
upon treatment with factor Xa or preincubation of the
cells with EGF (data not shown). In conclusion, the EGF
domain was found to block cell entry of SNV-EGF vector
particles into D17 cells. The block to cell entry could be
released by removal of the EGF domain or blockage of
the EGFRs on the cell surface.
Next, we analyzed the behavior of vector particles with
mixed envelopes. In particular, we asked if the EGF-SU
proteins would exhibit a trans-dominant negative effect
over the wildtype Env proteins. For this purpose, vector
particles containing both the wildtype and the EGF-mod-
ified Env proteins were generated by cotransfection of
293T cells with the Env encoding plasmids at a 1:1 ratio.
With both the MLV and the SNV particles released from
the transfected cells, gene transfer into D17 cells was
very inefficient (Fig. 4A). However, digestion of the parti-
cles with factor Xa, preincubation of the cells with solu-
ble EGF, or a combination of both restored titers to
almost 105 EFU/ml. The numbers obtained were very
similar for both viruses (Fig. 4A). To prove if this trans-
dominant negative effect of the SNV EGF-SU protein was
dose dependent a panel of SNV vector stocks was pre-
pared after transfection of 293T cells with different ratios
of the wildtype and the EGF modified Env protein expres-
sion plasmids. As a negative control and to apply iden-
tical amounts of plasmid DNA in all transfections an
unrelated plasmid (pUC18) was added. The numbers
of infectious particles were then determined on D17
cells. More than a 10-fold inhibition of transduction was
detectable at a pRD134 to pRD134-EGF ratio of 0.2
(Fig. 4B: 0.5). At a 1:1 ratio of both plasmids (Fig. 4B: 2.5)
titers were reduced by about 500-fold compared to
the titers obtained in the absence of pRD134-EGF
(Fig. 4B).
FIG. 3. Titers of SNV and MLV vector particles harboring the homologous EGF-SU and TM proteins on D17 cells. Cells (1  105) were incubated
with vector containing cell supernatants under different conditions: either supernatants were treated with 1 g/ml of factor Xa before transduction
(Xa) or target cells were treated with 1  106 M soluble EGF before transduction (EGF), or both treatments were combined (Xa & EGF). (A) Titers
on D17 cells for MLV-EGF (dark gray) or SNV-EGF (light gray) vectors. Mean values from three experiments are shown, and standard deviations are
indicated by error bars. (B) X-Gal staining of D17 cells after transduction with SNV-EGF.
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DISCUSSION
The data underlying this report show that the fusion of
an EGF domain to the SNV Env proteins is not sufficient
to allow direct gene transfer into human EGFR-positive
cells using SNV-derived vector particles harboring such
EGF-Env proteins. Two different SNV-derived and EGF-
modified Env proteins were expressed in a suitable
packaging cell line: (i) an EGF-TM protein expressed
together with the wildtype SNV Env proteins and (ii) an
EGF-SU protein expressed in conjunction with the wild-
type SNV TM protein. It appears that the EGF-TM protein
may not have been incorporated at all or in insufficient
amounts to allow transduction of EGFR-positive cells. In
contrast, the EGF-SU protein was well expressed on the
cell surface, incorporated in amounts comparable with
those of the SNV wildtype Env protein, but prevented the
transduction of SNV permissive cell lines.
Using antibodies directed against the SNV TM protein
or against EGF, the EGF-TM protein was detected intra-
cellularly, but neither on the cell surface nor in the vector
particles released from the packaging cells. A very low
amount of the 7A5-scFv-TM had previously been de-
tected in vector particles able to transduce those human
cells that showed binding of the soluble form of the
7A5-scFv (Engelstaedter et al., 2000). The lack of cell
surface expression and the meagerness of incorporation
by SNV indicates that SNV-derived scFv-TM fusion pro-
teins are not ideally suitable for the generation of cell
targeting vectors. The lack of incorporation into SNV
vector envelopes may be due at least in part to the
FIG. 4. Transdominant negative effect of the EGF SU-TM protein on SNV WT-Env in respective SNV-derived vector particles. (A) Transdominant
negative effect of EGF-modified Env on WT-Env for MLV (dark gray) and SNV (light gray) particles. Packaging cells were transfected with equal
amounts of plasmids encoding WT-Env and EGF-SU/TM proteins (1 g each) and treated according to the description in the Fig. 3 legend. (B)
Packaging cell lines were transfected with 2.5 g of plasmid encoding SNV WT-Env and different amounts of plasmid encoding EGF-SU/TM (0–2.5
g). The amounts of total DNA used for transfection were equal in all samples.
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inefficient transport of the 7A5-scFv-TM or the EGF-TM
proteins to the cell surface. The N-terminus of the TM
protein is highly hydrophobic and normally covered by
the SU protein. In the 7A5-scFv-TM and in the EGF-TM
proteins, a long flexible glycine–serine linker, which can-
not be cleaved by the viral or cellular proteases, con-
nects the TM protein and the foreign domain and seems
insufficient to effectively shield the hydrophobic N-termi-
nal domains of the TM protein. This, in turn, may lead to
instability and degradation of these proteins and may
thus contribute to the lack of efficient cell surface pre-
sentation. Consequently, incorporation into SNV is re-
duced or may be lacking at all. In contrast, the EGF-SU
protein expressed in conjunction with the wildtype TM
protein was presented at the cell surface and could be
readily detected using the monoclonal antibody directed
against EGF. Consequently, incorporation into SNV vec-
tor particles as reported here was efficient and compa-
rable with that of the wildtype SNV Env proteins. The
latter property is shared between the SNV and the MLV
Env proteins. MLV-derived EGF-SU and wildtype TM pro-
teins have been shown to be well expressed at the cell
surface of suitable packaging cells and are readily in-
corporated into MLV (Ager et al., 1996).
It has previously been shown that SNV-derived vectors
harboring scFv-SU/TM or scFv-TM proteins in their en-
velopes allow direct cell targeting. The lack of transduc-
tion of human EGFR-positive cells by SNV vectors carry-
ing EGF-SU proteins in their envelope, as reported here,
is therefore surprising. However, the block in transduc-
tion was observed on SNV permissive canine D17 cells
as well and could be overcome by removing the EGF
domain from the SU protein proteolitically using an in-
serted factor Xa cleavage site. The transduction block
was also removed by blocking the EGFRs on the cell
surface of D17 cells, which allowed cell entry via the
presumed natural SNV receptor present on D17 cells.
These properties of the SNV-EGF vector particles are
similar to those of MLV-EGF particles. They may there-
fore be explained by the same model that has been
invoked to explain the lack of target cell transduction by
MLV vectors harboring MLV EGF-SU proteins. The model
termed “receptor-mediated sequestration” (Cosset et al.,
1995) invokes strong binding of the respective vectors to
EGFR on the cell surface, therefore inhibiting binding to
the natural virus receptor and cell entry.
Another surprising outcome of this study was the high
extent of proteolytic activation observed for the EGF-SNV
vector particles. On both SNV permissive cell lines avail-
able, activation was almost 100-fold more efficient than
that with MLV. Moreover, experiments performed with
mixed envelopes demonstrated a dose-dependent trans-
dominant negative effect on vector titers of the EGF-SU
protein over the wildtype SNV Env protein. Based on the
amounts of plasmid DNA used, it can be estimated that
one single EGF-SU molecule per Env protein trimer is
sufficient to reduce the titer approximately 100-fold. In
MLV, blocking of cell entry mediated by the displayed
EGF molecule has been shown to depend on the ratio of
the number of EGFR molecules and of virus receptor
molecules expressed on the cell surface (Nilson et al.,
1996; Chadwick et al., 1999). Cells with a low EGFR
density allow entry of MLV-EGF particles at almost wild-
type efficiency, whereas tumor cell lines with high EGFR
densities, e.g., A431, exhibit the strongest blocking effect
(Peng et al., 1999). Thus, for SNV-EGF vectors such as
those used here this may imply that D17 cells express a
lower number of SNV receptor molecules than MLV re-
ceptor molecules. Alternatively, the affinity of SNV for its
receptor on D17 cells may be lower than that of MLV for
its receptor.
Theoretically, the EGF domain fused to the SNV SU
protein may reduce the infectivity of respective SNV-EGF
vectors due not only to receptor-mediated sequestration
but also to steric hindrance of the interaction between
SU and the virus receptor on D17 cells. For MLV, the
latter mechanism was shown to inhibit infectivity of MLV
vector particles harboring an SU protein modified with a
scFv-domain inserted at amino acid position seven or if
trimerizing ligands were used to modify the SU protein
(Ager et al., 1996; Morling et al., 1997). In these cases,
however, pretreatment of the target cells with EGF does
not lead to an increase in the observable titers because
the steric hindrance is not influenced by this. For SNV,
pretreating the cells with EGF or cleaving off the EGF
domain resulted in similar overall titers. Thus, steric
hindrance of the SU/receptor contact by the EGF domain
itself seemed not to cause the observed inhibition of cell
entry of SNV. Therefore, insertion of EGF domains at the
ultimate N-terminus of the SU protein keeps the respec-
tive SNV vector particles fully infectious.
Overall, the results described here show that SNV and
MLV vectors harboring EGF-SU/TM proteins in their en-
velopes share certain properties, including the inability
to directly transduce EGFR-positive target cells. Target
cell transduction via the natural receptors is restored by
removal of the EGF domain, implying attachment of the
vector particles to the EGFR. In MLV, this observation led
to the design of indirect targeting strategies, like pro-
tease activation or inverse targeting, relying on the bind-
ing to the retargeted receptor and cell entry through the
natural receptor (Buchholz et al., 1999). As there is no
SNV receptor expressed on human cells, targeting of
SNV vectors requires direct strategies and therefore
strongly depends on the properties of the retargeted
receptor. The selection of suitable ligand/receptor pairs
by the use of display libraries should therefore be the
approach of choice (Engelstaedter et al., 2000). Apart
from this, the high extent of proteolytic activation ob-
served for SNV-EGF vector particles suggests that they
might be superior to MLV in high throughput screens for
compounds that interfere with the EGF/EGF receptor
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interaction (Chadwick et al., 1999) or for protease sub-
strate peptides from retroviral peptide display libraries
(Buchholz et al., 1998).
MATERIALS AND METHODS
Plasmid construction
The SNV envelope expression construct pRD134corr,
the scFv-SNV-TM fusion protein encoding expression
construct pTC53-7A5, as well as the EGF-modified MLV
envelope expression constructs pEMO and pSALV have
been described previously (Engelstaedter et al., 2001,
2000; Buchholz et al., 1998; Cosset et al., 1995). pEMO
served as template for the amplification of the EGF
domain in a standard PCR. Primers CB1(), 5-
GCGGCCCAGCCGGCCGATTATAAGGACGACGATGAT-
AAGGCTAGCGCTAATAGTGACTCTGAGTGTCC-3, and
MEGF(), 5-AGATTTGCGGCCGCCCTTCCCTCGAT-
AGCGCTAGCCAGTTCCCACCACTTCAGG-3, were used
to introduce a flag tag and the factor Xa site. The frag-
ment was digested with SfiI and NotI and ligated via
these restriction sites into pTC53-7A5. The resulting ex-
pression construct pTC53-EGF served as template for
the generation of pRD134-EGF using the primers
pTC53SacII(), 5-CCTAGCCGCGGCCACCGCCATG-
GACTCTCTCACCAACCTC-3, and pTC53BstEII(), 5-
TATTTGGTAACCTTCGGCTGCGGCCGCCCGTCCCTCG-
3. The amplified fragment was inserted into pRD134corr
via SacII and BstEII. For the generation of pEXA, pTC53-
EGF was digested with SfiI and NotI. The resulting EGF
fragment was then inserted into pSALV via these restric-
tion sites.
Cells and antibodies
D17 cells (dog osteosarcoma cell line), A431 (human
vulva carcinoma cells), HT1080 (human fibrosarcoma
cells), and MDCK (Madin–Darby canine kidney cells)
were grown in Dulbecco’s minimal essential medium
(DMEM; Gibco, Eggenstein, Germany) containing 10%
heat-inactivated fetal calf serum (FCS; Biochrom, Berlin,
Germany) supplemented with 2 mM L-glutamine and
antibiotics.
A monoclonal antibody specific for the TM peptide of
SNV (Cui et al., 1986), 11A25, was kindly provided by L.
Lee (Regional Poultry Research Laboratory, East Lan-
sing, Michigan). A monoclonal antibody raised against
human EGF was obtained from Sigma, Deisenhofen
(Clone EGF-10).
Vector stocks and transduction experiments
Transfection of 1  106 293T cells seeded in 25-cm2
culture flasks (Nunc, Wiebaden, Germany) 24 h prior
transfection was performed using a total amount of 6 g
of plasmid DNA (if not otherwise stated, 2 g of each
plasmid). Following expression, plasmids were applied
additionally to the Env protein encoding constructs:
pRD136 encodes SNV gag/pol, pCXL is a lacZ encoding
SNV transfer vector (Martinez and Dornburg, 1995; Mi-
kawa et al., 1991); pHIT456 and pHIT60 encode the
amphotropic MLV Env proteins, respectively MLV gag/
pol; pMfgLacZ is a lacZ encoding MLV transfer vector
(Soneoka et al., 1995; Ferry et al., 1991). Transfection was
performed with Lipofectamine Plus (Gibco, Eggenstein,
Germany) according to the manufacturer’s instructions
using 6 l of Plus reagent and 15 l of Lipofectamine per
6 g of DNA.
Supernatants of transient transfections (1.5 ml) were
collected 48 h after transfection, filtered (0.45 m, Sar-
torius), and incubated with 1  105 cells for 2 h in the
presence of 30 g/ml (SNV particles) of polybrene (hexy-
dimethrine bromide–dimethyl sulfoxide) at 8 g/ml (MLV
particles). To determine the number of cells expressing
the bacterial lacZ gene, cells were stained 48 h after
infection with 5-bromo-4-chloro-3-indolyl--D-galactopyr-
anoside (X-Gal, Sigma, Deisenhofen, Germany) as de-
scribed elsewhere (Mikawa et al., 1991) and blue cells
were counted at 200-fold magnification.
Determination of blocking efficiency was performed as
described previously (Cosset et al., 1995; Nilson et al.,
1996). Supernatants were supplemented with 1 g/ml of
factor Xa (NEB, Frankfurt, Germany) and 2 mM CaCl2 and
incubated at 37°C for 1.5 h. Alternatively, target cell
medium was supplemented with 1 M soluble EGF (R&D
Systems) 30 min prior to transduction. In this case, the
supernatant was also supplemented with 1 M soluble
EGF. A combination of factor Xa cleavage and competi-
tion with soluble EGF was performed, too.
Fluorescence-activated cell scan (FACS)
For FACS analysis 5  105 transfected cells were
washed with PBA (PBS with 2% FCS and 0.1% sodium
azide) and incubated with the -EGF antibody in a 1:100
dilution for 45 min at 4°C. After washing with PBA, cells
were incubated with 1:50 diluted phycoerythrin (PE)-la-
beled secondary antibodies directed against mouse IgG
(Sigma) for 30 min. After washing, cells were fixed in
PBS/1% paraformaldehyde and subjected to FACS anal-
ysis (FACScan, Becton–Dickinson, San Jose, CA). For the
detection of EGF receptor, cells were incubated with 1
g/ml of fluorescence-labeled EGF (Alexa Fluor 488,
Molecular Probes) instead of antibodies. Subsequently
FACS analysis was performed as described above.
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